Down 60%: Is the Magellan (ASX:MFG) share price now a bargain?

Are Magellan shares an opportunity after dropping around 60%?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Magellan Financial Group Ltd (ASX: MFG) share price has fallen approximately 60% over the past year. Is the fund manager now a bargain buy after all of its troubles?

Magellan shares have been drifting lower for quite a long time. Worries about its investment fund performance caused concerns regarding funds under management (FUM) retention and the ability to maintain its management fees.

It was a week before Christmas that Magellan received the news that its biggest client was pulling its funds out.

arrow and dissapointed man showing the stock market crashing

Image source: Getty Images

Loss of St James' Place mandate

Magellan was notified on 17 December 2021 that St James' Place had terminated its mandate.

That mandate, which was a separate account and not an investment in any of Magellan's retail global funds, represented approximately 12% of its current annual revenue and is anticipated to have an impact of around 6% on the FY22 revenue.

Due to the timing to the mandate loss, the impact will be immaterial to the company's half-year result to 31 December 2021.

Magellan co-founder Hamish Douglass noted in a video that no other client amounts to more than 3% of its revenue. The Magellan business, Mr Douglass noted, was diversified and in a strong financial position with strong assets and cash. It continues to have high profit margins and good cashflow.

The Magellan share price has dropped 28% since this news dropped.

Resignation of CEO

About a month ago, Magellan announced that its CEO, Dr Brett Cairns, was resigning for personal reasons and will be leaving the company.

The chief financial officer (CFO) of Magellan, Ms Kirsten Morton, has been appointed as the interim CEO. She has been CFO for eight years and has a "detailed understanding of Magellan and its operations" after joining the senior management team in 2013.

Mr Hamish Douglass will remain as Magellan's executive Chair.

Is the Magellan share price an opportunity?

There are a mixture of views on the business.

Despite the heavy decline of the share price, UBS thinks there could be further declines on the potential loss of other clients. The broker has a price target of $17, which would suggest a potential drop of around 20%. UBS is expecting more than $20 billion of net outflows of funds under management over the next few years and increased pressure of management fees.

Morgan Stanley also reckons that Magellan is a sell/underweight with a price target of $17.50. It is concerned that the underperformance could lead to a decline in the management fees that it charges the retail clients.

However, not every analyst is pessimistic about where the Magellan share price is headed. Morgans currently rates Magellan as a hold, but it has a price target of $24.15 – that's 15% higher than where it is right now. But, fee pressure and net outflows are also a concern for Morgans.

Whilst the core equity strategy may be under pressure, Magellan has pointed to various other parts of the business which have growth potential in the coming years including its Australian equity strategies, its retirement product called Futurepay, its sustainable investing strategies and its investments in other businesses like Barrenjoey and Guzman y Gomez.

Motley Fool contributor Tristan Harrison owns Magellan Financial Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

A man in his office leans back in his chair with his hands behind his head looking out his window at the city, sitting back and relaxed, confident in his ASX share investments for the long term.
Broker Notes

Buy, hold, sell: Endeavour, Magellan, and Rio Tinto shares

The team at Morgans has been running the rule over these shares recently.

Read more »

A man casually dressed looks to the side in a pensive, thoughtful manner with one hand under his chin, holding a mobile phone in his hand while thinking about something.
Broker Notes

Should you buy Coles, Light & Wonder, and TPG Telecom shares in April?

Let's see if the team at Morgans rates these shares as buys ahead of the new month.

Read more »

Focused man entrepreneur with glasses working, looking at laptop screen thinking about something intently while sitting in the office.
Broker Notes

Buy, hold, sell: Northern Star, Telix, and Virgin Australia shares

Let’s see if they are bullish or bearish on these names.

Read more »

A man looking at his laptop and thinking.
Broker Notes

Forget CBA shares and buy this ASX ETF: experts

Here's what experts are saying about these two investment options.

Read more »

Middle age caucasian man smiling confident drinking coffee at home.
Broker Notes

Buy, hold, sell: BHP, Guzman Y Gomez, and Pro Medicus shares

Are brokers bullish or bearish on these names? Let's find out.

Read more »

Red buy button on an Apple keyboard with a finger on it.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to buy these shares.

Read more »

Humanoid robot analysing the stock market, symbolising artificial intelligence shares.
Broker Notes

Up 109% since November, are Appen shares still a buy today?

A leading expert digs into the outlook for Appen shares amid the rise of AI.

Read more »

A white and black clock face is shown with three hands saying Time to Buy reflecting Citi's view that it's time to buy ASX 200 banks
Broker Notes

3 reasons to buy Pro Medicus shares today

Two leading investment analysts believe Pro Medicus shares are primed for a rebound.

Read more »